|
1. Glozak MA, Sengupta N, Zhang X, Seto E: Acetylation and deacetylation of non-histone proteins. Gene 2005, 363:15-23. 2. Pan LN, Lu J, Huang B: HDAC inhibitors: a potential new category of anti-tumor agents. Cell Mol Immunol 2007, 4(5):337-343. 3. Feinberg AP, Ohlsson R, Henikoff S: The epigenetic progenitor origin of human cancer. Nat Rev Genet 2006, 7(1):21-33. 4. Jenuwein T, Allis CD: Translating the histone code. Science 2001, 293(5532):1074-1080. 5. Cosgrove MS, Wolberger C: How does the histone code work? Biochem Cell Biol 2005, 83(4):468-476. 6. Mutskov V, Felsenfeld G: Silencing of transgene transcription precedes methylation of promoter DNA and histone H3 lysine 9. EMBO J 2004, 23(1):138-149. 7. Fraga MF, Ballestar E, Villar-Garea A, Boix-Chornet M, Espada J, Schotta G, Bonaldi T, Haydon C, Ropero S, Petrie K et al: Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer. Nat Genet 2005, 37(4):391-400. 8. Wade PA: Transcriptional control at regulatory checkpoints by histone deacetylases: molecular connections between cancer and chromatin. Hum Mol Genet 2001, 10(7):693-698. 9. Yoshida M: [Potent and specific inhibition of mammalian histone deacetylase both in vivo and in vitro by trichostatin A]. Tanpakushitsu Kakusan Koso 2007, 52(13 Suppl):1788-1789. 10. Hong J, Ishihara K, Yamaki K, Hiraizumi K, Ohno T, Ahn JW, Zee O, Ohuchi K: Apicidin, a histone deacetylase inhibitor, induces differentiation of HL-60 cells. Cancer Lett 2003, 189(2):197-206. 11. Richon VM, Sandhoff TW, Rifkind RA, Marks PA: Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation. Proc Natl Acad Sci U S A 2000, 97(18):10014-10019. 12. Qiu L, Burgess A, Fairlie DP, Leonard H, Parsons PG, Gabrielli BG: Histone deacetylase inhibitors trigger a G2 checkpoint in normal cells that is defective in tumor cells. Mol Biol Cell 2000, 11(6):2069-2083. 13. Jung JH, Sim CJ, Lee CO: Cytotoxic compounds from a two-sponge association. J Nat Prod 1995, 58(11):1722-1726. 14. Li CJ, Schmitz FJ, Kelly-Borges M: A new lysine derivative and new 3-bromopyrrole carboxylic acid derivative from two marine sponges. J Nat Prod 1998, 61(3):387-389. 15. Shim JS, Lee HS, Shin J, Kwon HJ: Psammaplin A, a marine natural product, inhibits aminopeptidase N and suppresses angiogenesis in vitro. Cancer Lett 2004, 203(2):163-169. 16. Godert AM, Angelino N, Woloszynska-Read A, Morey SR, James SR, Karpf AR, Sufrin JR: An improved synthesis of psammaplin A. Bioorg Med Chem Lett 2006, 16(12):3330-3333. 17. Liu S, Fu X, Schmitz FJ, Kelly-Borges M: Psammaplysin F, a new bromotyrosine derivative from a sponge, Aplysinella sp. J Nat Prod 1997, 60(6):614-615. 18. Park Y, Liu Y, Hong J, Lee CO, Cho H, Kim DK, Im KS, Jung JH: New bromotyrosine derivatives from an association of two sponges, Jaspis wondoensis and Poecillastra wondoensis. J Nat Prod 2003, 66(11):1495-1498. 19. Pina IC, Gautschi JT, Wang GY, Sanders ML, Schmitz FJ, France D, Cornell-Kennon S, Sambucetti LC, Remiszewski SW, Perez LB et al: Psammaplins from the sponge Pseudoceratina purpurea: inhibition of both histone deacetylase and DNA methyltransferase. J Org Chem 2003, 68(10):3866-3873. 20. Tabudravu JN, Eijsink VG, Gooday GW, Jaspars M, Komander D, Legg M, Synstad B, van Aalten DM: Psammaplin A, a chitinase inhibitor isolated from the Fijian marine sponge Aplysinella rhax. Bioorg Med Chem 2002, 10(4):1123-1128. 21. Kim DH, Shin J, Kwon HJ: Psammaplin A is a natural prodrug that inhibits class I histone deacetylase. Exp Mol Med 2007, 39(1):47-55. 22. Mora FD, Jones DK, Desai PV, Patny A, Avery MA, Feller DR, Smillie T, Zhou YD, Nagle DG: Bioassay for the identification of natural product-based activators of peroxisome proliferator-activated receptor-gamma (PPARgamma): the marine sponge metabolite psammaplin A activates PPARgamma and induces apoptosis in human breast tumor cells. J Nat Prod 2006, 69(4):547-552. 23. Ahn MY, Jung JH, Na YJ, Kim HS: A natural histone deacetylase inhibitor, Psammaplin A, induces cell cycle arrest and apoptosis in human endometrial cancer cells. Gynecol Oncol 2008, 108(1):27-33. 24. Shangary S, Wang S: Targeting the MDM2-p53 interaction for cancer therapy. Clin Cancer Res 2008, 14(17):5318-5324. 25. Attardi LD, Jacks T: The role of p53 in tumour suppression: lessons from mouse models. Cell Mol Life Sci 1999, 55(1):48-63. 26. Evans SC, Lozano G: The Li-Fraumeni syndrome: an inherited susceptibility to cancer. Mol Med Today 1997, 3(9):390-395. 27. Feki A, Irminger-Finger I: Mutational spectrum of p53 mutations in primary breast and ovarian tumors. Crit Rev Oncol Hematol 2004, 52(2):103-116. 28. Kubbutat MH, Vousden KH: Keeping an old friend under control: regulation of p53 stability. Mol Med Today 1998, 4(6):250-256. 29. Midgley CA, Lane DP: p53 protein stability in tumour cells is not determined by mutation but is dependent on Mdm2 binding. Oncogene 1997, 15(10):1179-1189. 30. Varshavsky A: The ubiquitin system. Trends Biochem Sci 1997, 22(10):383-387. 31. Momand J, Jung D, Wilczynski S, Niland J: The MDM2 gene amplification database. Nucleic Acids Res 1998, 26(15):3453-3459. 32. Wu X, Bayle JH, Olson D, Levine AJ: The p53-mdm-2 autoregulatory feedback loop. Genes Dev 1993, 7(7A):1126-1132. 33. Marston NJ, Crook T, Vousden KH: Interaction of p53 with MDM2 is independent of E6 and does not mediate wild type transformation suppressor function. Oncogene 1994, 9(9):2707-2716. 34. Reinke V, Lozano G: The p53 targets mdm2 and Fas are not required as mediators of apoptosis in vivo. Oncogene 1997, 15(13):1527-1534. 35. Momand J, Zambetti GP, Olson DC, George D, Levine AJ: The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell 1992, 69(7):1237-1245. 36. Oliner JD, Pietenpol JA, Thiagalingam S, Gyuris J, Kinzler KW, Vogelstein B: Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53. Nature 1993, 362(6423):857-860. 37. Chene P: Inhibiting the p53-MDM2 interaction: an important target for cancer therapy. Nat Rev Cancer 2003, 3(2):102-109. 38. Freedman DA, Levine AJ: Nuclear export is required for degradation of endogenous p53 by MDM2 and human papillomavirus E6. Mol Cell Biol 1998, 18(12):7288-7293. 39. Haupt Y, Maya R, Kazaz A, Oren M: Mdm2 promotes the rapid degradation of p53. Nature 1997, 387(6630):296-299. 40. Honda R, Tanaka H, Yasuda H: Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53. FEBS Lett 1997, 420(1):25-27. 41. Kubbutat MH, Ludwig RL, Levine AJ, Vousden KH: Analysis of the degradation function of Mdm2. Cell Growth Differ 1999, 10(2):87-92. 42. Tyers M, Willems AR: One ring to rule a superfamily of E3 ubiquitin ligases. Science 1999, 284(5414):601, 603-604. 43. Roth J, Dobbelstein M, Freedman DA, Shenk T, Levine AJ: Nucleo-cytoplasmic shuttling of the hdm2 oncoprotein regulates the levels of the p53 protein via a pathway used by the human immunodeficiency virus rev protein. EMBO J 1998, 17(2):554-564. 44. Lain S, Midgley C, Sparks A, Lane EB, Lane DP: An inhibitor of nuclear export activates the p53 response and induces the localization of HDM2 and p53 to U1A-positive nuclear bodies associated with the PODs. Exp Cell Res 1999, 248(2):457-472. 45. Stommel JM, Marchenko ND, Jimenez GS, Moll UM, Hope TJ, Wahl GM: A leucine-rich nuclear export signal in the p53 tetramerization domain: regulation of subcellular localization and p53 activity by NES masking. EMBO J 1999, 18(6):1660-1672. 46. Tao W, Levine AJ: Nucleocytoplasmic shuttling of oncoprotein Hdm2 is required for Hdm2-mediated degradation of p53. Proc Natl Acad Sci U S A 1999, 96(6):3077-3080. 47. Oliver FJ, de la Rubia G, Rolli V, Ruiz-Ruiz MC, de Murcia G, Murcia JM: Importance of poly(ADP-ribose) polymerase and its cleavage in apoptosis. Lesson from an uncleavable mutant. J Biol Chem 1998, 273(50):33533-33539. 48. Li LC, Carroll PR, Dahiya R: Epigenetic changes in prostate cancer: implication for diagnosis and treatment. J Natl Cancer Inst 2005, 97(2):103-115. 49. Takai N, Desmond JC, Kumagai T, Gui D, Said JW, Whittaker S, Miyakawa I, Koeffler HP: Histone deacetylase inhibitors have a profound antigrowth activity in endometrial cancer cells. Clin Cancer Res 2004, 10(3):1141-1149. 50. Marks PA, Richon VM, Rifkind RA: Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells. J Natl Cancer Inst 2000, 92(15):1210-1216. 51. Liu S, Bishop WR, Liu M: Differential effects of cell cycle regulatory protein p21(WAF1/Cip1) on apoptosis and sensitivity to cancer chemotherapy. Drug Resist Updat 2003, 6(4):183-195. 52. Ashcroft M, Vousden KH: Regulation of p53 stability. Oncogene 1999, 18(53):7637-7643.
|